Skip to main content
. Author manuscript; available in PMC: 2021 Jan 9.
Published in final edited form as: Adv Cancer Res. 2020 Jul 9;148:69–146. doi: 10.1016/bs.acr.2020.05.002

Figure 6. Comparative structures of KRAS(G12C) inhibitors.

Figure 6.

(A) Shokat cmpd 16 (PDB: M422); (B) ARS1620 (PDB:5V9U); (C) MRTX cmpd12 (PDB: 6N2K); (D) AMG510 (PDB: 6OIM). Coloring is the same as described in Fig. 2A